4Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus:the 10 year follow-up of the Belfast Diet Study.Diabet Med 1998; 15:290-296.
5Hirsch IB,Bergenstal RM,Parkin CG,Wright E,Buse JB:A real-world approach to insulin therapy in primary care practice.Clin Diabetes 2005,23:78-86.
6Steven E.Kahn,Steven M.Haffner,Mark A.et al.Glycemic Durability of Rosiglitazone,Metformin,or Glyburide Monotherapy.N Eng J Med 2006;355:2427-2443.
7DeFronzo R,Ratner RE,Han J,Kim DD,Fineman MS,Baron AD:Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care 2005; 28:1092-1100.
8Hollander PA,Levy P,Fineman MS,Maggs DG,Shen LZ,Strobel SA,Weyer C,Kolterman OG:Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes.Diabetes Care 2003; 26:784-790.
9David M.Nathan,MD,John B.Buth MD,PhD,Mayer B.Davidson,MD.Et al.Management of hyperglycemia in type 2 diabetes:a consensus algorithm for the initiation and adjustment of therapy.Diabetes Care 2006 ;29:1965-1972.
